News Pfizer builds on Braftovi bowel cancer OK with survival data Pfizer's Braftovi - just approved by the FDA as a first-line treatment for colorectal cancer based on response data - also extends patient survival.
News Pfizer offers $60m to settle prescriber kickback claims Pfizer has paid $60m to settle US government allegations that its Biohaven unit made improper payments to prescribers of its migraine drug Nurtec ODT.
Digital In conversation at Veeva Summit: Jonathan Crowther, Pfizer At the Veeva Commercial Summit in Madrid at the end of 2024, pharmaphorum web editor Nicole Raleigh sat down with Pfizer’s head of predictive analytics, Jonathan Crowther, to discuss the ro
News 11 blockbuster drugs to look out for in 2025 Clarivate has revealed 11 drugs due to launch in 2025 that could top $1 billion in annual sales or be clinical 'game changers' in the next five years.
News Pfizer ducks out of Sangamo haemophilia A alliance Sangamo is "surprised and disappointed" by Pfizer's decision to return rights to its gene therapy for haemophilia A after positive phase 3 results.
News FDA approves flurry of drugs ahead of holiday season The FDA has wrapped up a series of new approvals as 2024 draws to a close, with Novo Nordisk, Pfizer, Vertex, and Hikma among the beneficiaries.
News Europe is facing a surge in STIs, says ECDC Cases of sexually-transmitted infections (STIs) – particularly gonorrhoea and syphilis – are at record levels across 29 European countries.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.